Abstract:Qian Shen, 1 Shenhua Jiang, 2 Mingyun Wu, 2 Lei Zhang, 3 Xue Su, 1 Ding Zhao 4 1 Department of Nephrology, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200062, People's Republic of China; 2 Department of Pediatrics, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, People's Republic of China; 3 School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People's Republic of China; 4 Department of Oncology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng, Jiangsu, 224000, People's Republic of China Correspondence: Ding Zhao Department of Oncology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, No. 53 North Renmin Road, Yancheng, Jiangsu 224000, People's Republic of China Tel +86-15951612124 Email bbswpa@163.com Background: The hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA (HEIH) has been identified to act as an oncogene to promote cell tumorigenesis in hepatocellular carcinoma (HCC); however, the roles of HEIH in sorafenib resistance in HCC cells remain elusive. Materials and Methods: The expression of HEIH and microRNA (miR)-98-5p was detected using quantitative real-time polymerase chain reaction. Cell viability, apoptosis, migration and invasion were analyzed using cell counting kit-8 assay, flow cytometry and transwell assay. Western blot was used to measure the levels of apoptosis-related protein and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway-related protein. The interaction between HEIH and miR-98-5p was confirmed by dual-luciferase reporter and RNA immunoprecipitation assay. In vivo experiments were performed using murine xenograft models. Results: HEIH was up-regulated in sorafenib-resistant HCC tissues and cell lines, and HEIH silence weakened sorafenib resistance by suppressing cell viability, invasion and migration, decreasing the IC 50 values to sorafenib, and increasing apoptosis in sorafenib-resistant HCC cells in vitro and reinforced the anti-tumor effects of sorafenib in vivo. HEIH was a sponge of miR-98-5p, and miR-98-5p inhibition reversed the sorafenib sensitivity induced by HEIH deletion in sorafenib-resistant HCC cells. MiR-98-5p inhibition could activate PI3K/AKT pathway, and enhanced sorafenib resistance by regulating the activation of PI3K/AKT pathway in sorafenib-resistant HCC cells. Besides, HEIH also activated PI3K/AKT pathway through regulating miR-98-5p in sorafenib-resistant HCC cells. Conclusion: HEIH conferred an advantage to sorafenib resistance in HCC by the activation of PI3K/AKT pathway through miR-98-5p, indicating a potential therapeutic strategy for HCC chemotherapy. Keywords: HEIH, miR-98-5p, PI3K/AKT, HCC, chemoresistance

IGF-1R Down Regulates the Sensitivity of Hepatocellular Carcinoma to Sorafenib Through the PI3K / Akt and RAS / Raf / ERK Signaling Pathways

Inhibition of the Wnt/β-catenin Signaling Pathway Improves the Anti-Tumor Effects of Sorafenib Against Hepatocellular Carcinoma.

Activation of Phosphatidylinositol 3-Kinase/akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Upregulation of HIF-2α Induced by Sorafenib Contributes to the Resistance by Activating the TGF-α/EGFR Pathway in Hepatocellular Carcinoma Cells

Lentivirus-Mediated Rnai Knockdown of Insulin- Like Growth Factor-1 Receptor Inhibits the Growth and Invasion of Hepatocellular Carcinoma Via Down-Regulating Midkine Expression

Abnormal Expression of Insulin-Like Growth Factor-I Receptor in Hepatoma Tissue and Its Inhibition to Promote Apoptosis of Tumor Cells

Downregulation Of Amplified In Breast Cancer 1 Contributes To The Anti-Tumor Effects Of Sorafenib On Human Hepatocellular Carcinoma

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.

Insulin-Like Growth Factor 1 Receptor Promotes the Growth and Chemoresistance of Pancreatic Cancer

Knockdown of insulin-like growth factor I receptor inhibits the growth and enhances chemo-sensitivity of liver cancer cells

NT157 Inhibits Hepatocellular Carcinoma Growth and Sensitizes Cells to Sorafenib

Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma

siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells

Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.

Sirna-Mediated Type 1 Insulin-Like Growth Factor Receptor Silencing Induces Chemosensitization of a Human Liver Cancer Cell Line with Mutant P53

Sorafenib Inhibits Proliferation and Invasion of Human Hepatocellular Carcinoma Cells Via Up-Regulation of P53 and Suppressing FoxM1

Effect of RNAi-mediated IGF1R gene silencing on growth, migration, and invasion of hepatocellular carcinoma cells

Cancer-associated fibroblasts promote the progression and chemoresistance of HCC by inducing IGF-1

LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway